Goflikicept

Goflikicept (RPH 104) is a fusion protein that selectively binds and inactivates both circulating IL-1β and IL-1α. Goflikicept has the potential for the research of ST-segment elevation myocardial infarction (STEMI) [1].

Product Specifications

CAS Number

[2416984-26-2]

Product Name Alternative

RPH 104

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/goflikicept.html

Purity

98.32

Solubility

10 mM in DMSO

Smiles

[Goflikicept]

Molecular Weight

(126.22 kDa)

References & Citations

[1]Samsonov M, et al. Interleukin-1 blockade with RPH-104 in patients with acute ST-elevation myocardial infarction: study design and rationale. J Transl Med. 2021 Apr 26;19 (1) :169.